The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) Resource in Neuro-Oncology

Abstract

In early 2016, the US Food and Drug Administration (FDA) and National Institutes of Health (NIH) published the first version of the glossary included in the Biomarkers, EndpointS, and other Tools (BEST) Resource¹. The BEST glossary was constructed to harmonize and clarify terms used in translational science and medical product development and to provide a common language used for communication by those agencies. It is considered a "living" document that will be updated in the future. This review will discuss the main biomarker and clinical outcome categories contained in the BEST glossary as they apply to neuro-oncology, as well as the overlapping and hierarchical relationships among them.